ClinicalTrials.gg
Active, not recruitingNCT06389136Switch-UpUpdated Oct 16, 2026

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

A Phase 3 interventional study of Upadacitinib 15mg Dose and Dupilumab 300mg Dose in Atopic Dermatitis, sponsored by AbbVie. Active, not recruiting at 129 sites in 9 countries. Open to participants aged 18 Years to 63 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
10th of 17
184 · median 272
Started
2024
with 3 others
Phase 3
12 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 10th largest by enrollment, is one of 4 that started in 2024, is one of 12 in phase 3, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 63 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Upadacitinib
  • Rinvoq
  • ABT-494
04

Who can participate

Ages eligible
18 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic AD with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria.
  • Participant meets all the following disease activity criteria at Baseline Visit:

    • Eczema Area and Severity Index (EASI) score >= 12;
    • validated Investigator´s Global Assessment for AD (vIGA-AD) score >= 3;
    • Body surface area (BSA) involvement of >= 10% in a majority of subjects (>= 50% of the overall study population)
    • Baseline weekly average of daily Worst Pruritus-Numerical Rating Scale (WP-NRS) >= 4. Note: The Baseline weekly average of daily WP-NRS will be calculated from the 7 consecutive days immediately preceding the Baseline Visit. A minimum of 4 daily scores out of the 7 days is needed.
    • Inadequate response to dupilumab treatment after at least 4 months of current use.
    • Particpant has applied a topical emollient (an additive-free, bland emollient moisturizer) twice daily for at least 7 days before the Baseline Visit and for the duration of the study. Note: Subject may use prescription moisturizers or moisturizers containing ceramide, urea, filaggrin degradation products or hyaluronic acid if such moisturizers were initiated before the Screening visit.

Exclusion criteria

Exclusion Criteria:

  • Meeting any of the following conditions at Baseline:

    • Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline Visit or would interfere with assessment of AD lesions;
    • Two or more past episodes of herpes zoster, or one or more episodes of disseminated herpes zoster;
    • One or more past episodes of disseminated herpes simplex (including eczema herpeticum);
    • infection defined as confirmed positive anti- HIV Ab test;
    • Participants with current or past history of infection including, Evidence of virus (HBV) or virus (HCV);
    • Active TB or meet TB exclusionary parameters (specific requirements for TB testing are provided in the operations manual);
    • For Japan: Positive result of beta-D-glucan (screening for Pneumocystis jirovecii infection) or two consecutive indeterminate results of beta-D-glucan during the Screening Period;
    • Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit;
    • Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study;
    • COVID-19 infection: In subjects who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the Baseline visit of asymptomatic subjects. Subjects with mild/moderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Subjects may be rescreened if deemed appropriate by the investigator based upon the subject's health status.
  • At Baseline any of the following medical diseases or disorders:

    • Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery or venous thromboembolism;
    • Any unstable clinical condition which, in the opinion of the investigator would put the subject at risk by participating in the protocol;
    • Diagnosed active parasitic infection, suspected or high risk of parasitic infection unless clinical (and if necessary) laboratory assessment have ruled out active infection before randomization;
    • History of an organ transplant which requires continued ;
    • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ) and/or other products in the same class;
    • History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;
    • Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery including sleeve gastrectomy; subjects with a history of gastric banding/segmentation are not excluded;
    • History of except for successfully treated NMSC or localized carcinoma in situ of the cervix.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Period 1: Upadacitinib Open Label Treatment

    Participants randomly assigned to receive Upadacitinib 15mg tablet once per day. Based on clinical response, participants randomized to Upadacitinib 15mg may have their dose increased to Upadacitinib 30mg starting at Week 2.

    Drug: Upadacitinib 15mg Dose · Drug: Upadacitinib 30mg Dose

  • Experimental
    Period 1: Dupilumab Open Label Treatment

    Participants randomly assigned to receive Dupilumab 300mg SC injection once every other week for 8 weeks.

    Drug: Dupilumab 300mg Dose

  • Experimental
    Period 2 Open Label: Upadacitinib < EASI 75 response

    Participants that were receiving Upadacitinib 15mg or 30mg and completed Period 1, will be allocated or continue to receive oral doses of Upadacitinib 30mg in Period 2 with a clinical response of \< EASI 75 at Week 8

    Drug: Upadacitinib 30mg Dose

  • Experimental
    Period 2 Open Label: Upadacitinib ≥ EASI 75 Response

    Participants that were receiving Upadacitinib 15mg or 30mg and completed Period 1, will continue to receive the same oral doses of Upadacitinib in Period 2 with a clinical response of ≥ EASI 75 at Week 8

    Drug: Upadacitinib 15mg Dose · Drug: Upadacitinib 30mg Dose

  • Experimental
    Period 2 Open Label: Dupilumab ≥ EASI 75 Response

    Participants that were receiving Dupilumab 300mg and completed Period 1, will continue to receive Dupilumab 300mg SC injection in Period 2 with a clinical response of ≥ EASI 75 at Week 8

    Drug: Dupilumab 300mg Dose

  • Experimental
    Period 2 Open Label Period: Dupilumab < EASI 75 Response

    Participants that were receiving Dupilumab 300mg SC injections and completed Period 1, will receive oral doses of Upadacitinib 15mg in Period 2 with a clinical response of \< EASI 75 at Week 8

    Drug: Upadacitinib 15mg Dose

Interventions

06

What researchers measure

Primary outcomes

  1. Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90)

    The EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points.

    Time frame: At Week 8

Secondary outcomes

  1. Percentage of participants who achieve a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1)

    Worst Pruritus NRS (WP-NRS) is a validated single self-reported measure where patients rate the worst level of itching they have experienced over the past 24 hours on a scale from 0 (no itching) to 10 (worst itching imaginable)

    Time frame: At Week 8

  2. Participants who simultaneous achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1)

    The EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Worst Pruritus NRS (WP-NRS) is a validated single self-reported measure where patients rate the worst level of itching they have experienced over the past 24 hours on a scale from 0 (no itching) to 10 (worst itching imaginable)

    Time frame: At Week 8

  3. Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1

    Worst Pruritus NRS (WP-NRS) is a validated single self-reported measure where patients rate the worst level of itching they have experienced over the past 24 hours on a scale from 0 (no itching) to 10 (worst itching imaginable)

    Time frame: At Week 4

07

Study locations

129 sites

Showing the first 100 of 129 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 29 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2026 → Nov 2026 and completion Mar 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Apr 29, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Nov 2026was Aug 2026
CompletionEst.
May 2027was Mar 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 16, 2026
Sites
13 sites added, 12 sites removed
Show 13 added (8 United States, 3 Colombia, 2 Canada)
  • Cahaba Dermatology and Skin Health Center /ID# 263855 · Birmingham, United States
  • First Oc Dermatology /ID# 263349 · Fountain Valley, United States
  • GSI Clinical Research /ID# 263760 · Margate, United States
  • Georgia Skin and Cancer Clinic /ID# 267199 · Savannah, United States
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 264983 · Chicago, United States
  • Skin Cancer and Dermatology Institute - Reno /ID# 263771 · Reno, United States
  • Studies in Dermatology /ID# 263335 · Cypress, United States
  • Fred Hutchinson Cancer Center - Seattle - Fairview Avenue North /ID# 264537 · Seattle, United States
  • York Dermatology Clinic and Research Centre /ID# 278847 · Richmond Hill, Canada
  • Centre de Recherche Saint-Louis /ID# 271083 · Québec, Canada
  • Centro de Inmunologia y Genetica CIGE SAS /ID# 266200 · Medellín, Colombia
  • Ips Sura San Diego /ID# 279456 · Medellín, Colombia
  • Centro Integral de Reumatologia del Caribe SAS - Circaribe SAS /ID# 265088 · Barranquilla, Colombia
Show 12 removed
  • Cahaba Dermatology & Skin Health Center /ID# 263855 · Birmingham, United States
  • First OC Dermatology /ID# 263349 · Fountain Valley, United States
  • Integrative Skin Science and Research /ID# 264537 · Sacramento, United States
  • GSI Clinical Research, LLC /ID# 263760 · Margate, United States
  • Georgia Skin & Cancer Clinic /ID# 267199 · Savannah, United States
  • Northwestern University Feinberg School of Medicine /ID# 264983 · Chicago, United States
  • Skin Cancer And Dermatology Institute (Scdi) - Reno /ID# 263771 · Reno, United States
  • Studies in Dermatology LLC /ID# 263335 · Cypress, United States
  • York Dermatology Clinic & Research Centre /ID# 278847 · Richmond Hill, Canada
  • Centre de Recherche Saint-Louis /ID# 271083 · Québec, Canada
  • Centro de Inmunología y Genética CIGE SAS /ID# 266200 · Medellín, Colombia
  • Centro Integral de Reumatología del Caribe SAS - Circaribe SAS /ID# 265088 · Barranquilla, Colombia
Oct 16, 2026
Primary completion
Aug 2026→Nov 2026
Oct 16, 2026
Study completion
Mar 2027→May 2027
Oct 16, 2026
Enrollment
200 (estimated)→184 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Active, not recruiting
    13 sites added, 12 sites removed
    Show 13 added (8 United States, 3 Colombia, 2 Canada)
    • Cahaba Dermatology and Skin Health Center /ID# 263855 · Birmingham, United States
    • First Oc Dermatology /ID# 263349 · Fountain Valley, United States
    • GSI Clinical Research /ID# 263760 · Margate, United States
    • Georgia Skin and Cancer Clinic /ID# 267199 · Savannah, United States
    • Northwestern Medicine - Northwestern Memorial Hospital /ID# 264983 · Chicago, United States
    • Skin Cancer and Dermatology Institute - Reno /ID# 263771 · Reno, United States
    • Studies in Dermatology /ID# 263335 · Cypress, United States
    • Fred Hutchinson Cancer Center - Seattle - Fairview Avenue North /ID# 264537 · Seattle, United States
    • York Dermatology Clinic and Research Centre /ID# 278847 · Richmond Hill, Canada
    • Centre de Recherche Saint-Louis /ID# 271083 · Québec, Canada
    • Centro de Inmunologia y Genetica CIGE SAS /ID# 266200 · Medellín, Colombia
    • Ips Sura San Diego /ID# 279456 · Medellín, Colombia
    • Centro Integral de Reumatologia del Caribe SAS - Circaribe SAS /ID# 265088 · Barranquilla, Colombia
    Show 12 removed
    • Cahaba Dermatology & Skin Health Center /ID# 263855 · Birmingham, United States
    • First OC Dermatology /ID# 263349 · Fountain Valley, United States
    • Integrative Skin Science and Research /ID# 264537 · Sacramento, United States
    • GSI Clinical Research, LLC /ID# 263760 · Margate, United States
    • Georgia Skin & Cancer Clinic /ID# 267199 · Savannah, United States
    • Northwestern University Feinberg School of Medicine /ID# 264983 · Chicago, United States
    • Skin Cancer And Dermatology Institute (Scdi) - Reno /ID# 263771 · Reno, United States
    • Studies in Dermatology LLC /ID# 263335 · Cypress, United States
    • York Dermatology Clinic & Research Centre /ID# 278847 · Richmond Hill, Canada
    • Centre de Recherche Saint-Louis /ID# 271083 · Québec, Canada
    • Centro de Inmunología y Genética CIGE SAS /ID# 266200 · Medellín, Colombia
    • Centro Integral de Reumatología del Caribe SAS - Circaribe SAS /ID# 265088 · Barranquilla, Colombia
    Primary completion Aug 2026→Nov 2026
    Study completion Mar 2027→May 2027
    Enrollment 200 (estimated)→184 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06389136
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Jun 14, 2024
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion